Federal Project Grant Award Summary

The National Cancer Institute awarded a $608,558 project grant under the Cancer Biology Research program (CFDA 93.396) to the Research Institute at Nationwide Children's Hospital, effective April 2, 2026 through March 31, 2031. This award supports fundamental research aimed at understanding the genetic and metabolic characteristics of high-risk neuroblastoma to develop novel precision and immunotherapy approaches. The research leverages genetically engineered mouse models to investigate how gamma-aminobutyric acid (GABA) metabolism contributes to tumor progression and immune suppression in pediatric neuroblastoma patients. Specific deliverables include characterization of immunocompetent animal models that replicate human high-risk neuroblastoma genomics and immunogenic properties, analysis of metabolic vulnerabilities in neuroblastoma cells, and development of therapeutic strategies targeting GABA metabolism to enhance immunotherapy effectiveness while reducing disease recurrence.

This Cancer Biology Research program award addresses a critical clinical need, as neuroblastoma represents the most common infant malignancy and causes approximately 15 percent of childhood cancer mortality, with current five-year survival rates for high-risk patients remaining at approximately 50 percent despite intensive treatment. The research outcomes are expected to generate fundamental insights into neuroblastoma oncogenesis mechanisms and produce translational findings that could inform the development of next-generation therapeutics with reduced toxicity profiles for pediatric cancer patients.